117 related articles for article (PubMed ID: 10586356)
21. Trying to improve clinical outcome in AML: lessons from negative trials.
Karp JE; Smith BD
Leuk Res; 2005 Jun; 29(6):603-4. PubMed ID: 15863196
[No Abstract] [Full Text] [Related]
22. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Helg C; Chapuis B; Grob JP; Pugin P
Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
[TBL] [Abstract][Full Text] [Related]
23. Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
Cavanna L; Di Stasi M; Fornari F; Civardi G; Sbolli G; Moretto M; Buscarini L
Eur J Haematol; 1990 Sep; 45(3):180-1. PubMed ID: 2226733
[No Abstract] [Full Text] [Related]
24. Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia.
Lee MH; Kim SY
Leuk Lymphoma; 2016 Oct; 57(10):2268-74. PubMed ID: 26750985
[TBL] [Abstract][Full Text] [Related]
25. First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.
Ahmed Z; Davaro E; Batanian J; Verma N
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31101747
[TBL] [Abstract][Full Text] [Related]
26. [Current situation and perspective for treatment of acute myelogenous leukemia in adults].
Fukushima T; Ueda T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):295-302. PubMed ID: 9492819
[TBL] [Abstract][Full Text] [Related]
27. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
[TBL] [Abstract][Full Text] [Related]
28. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Van Der Jagt R; Robinson KS; Belch A; Yetisir E; Wells G; Larratt L; Shustik C; Gluck S; Stewart K; Sheridan D;
Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
[TBL] [Abstract][Full Text] [Related]
29. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Keating MJ; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich EJ
Leukemia; 1992; 6 Suppl 2():78-80. PubMed ID: 1578950
[No Abstract] [Full Text] [Related]
30. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
31. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
[TBL] [Abstract][Full Text] [Related]
32. [Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Li XY; Wang X; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):67-8. PubMed ID: 23597470
[No Abstract] [Full Text] [Related]
33. Idarubicin oral: new formulation. No proven benefit over 60.
Prescrire Int; 2000 Aug; 9(48):103-5. PubMed ID: 11067717
[TBL] [Abstract][Full Text] [Related]
34. Idarubicin administered during pregnancy: its effects on the fetus.
Matsuo K; Shimoya K; Ueda S; Wada K; Koyama M; Murata Y
Gynecol Obstet Invest; 2004; 58(4):186-8. PubMed ID: 15256824
[TBL] [Abstract][Full Text] [Related]
35. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
36. [Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
Yata K; Yamada O; Iwato K; Kyo T; Otsuki T; Nakanishi H; Suetsugu Y; Mikami M; Wada H; Yawata Y; Sugihara T
Rinsho Ketsueki; 2002 Jan; 43(1):41-3. PubMed ID: 11868364
[TBL] [Abstract][Full Text] [Related]
37. Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
Haematol Blood Transfus; 1987; 30():393-8. PubMed ID: 3305209
[No Abstract] [Full Text] [Related]
38. Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Carella AM; Pungolino E; Piatti G; Giordano D; Cerri R; Risso M; Nati S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():50-1. PubMed ID: 2713562
[No Abstract] [Full Text] [Related]
39. Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients.
Pagano L; Sica S; Marra R; Voso MT; Storti S; Di Mario A; Leone G
Haematologica; 1991; 76(6):517-8. PubMed ID: 1820991
[TBL] [Abstract][Full Text] [Related]
40. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
